Follow the NervGen Pharma Corp. share price and the full management transaction log of the company, a listed issuer based in Canada. Shares trade on the CA market, under the oversight of SEDI. Operating in the Health Care sector, NervGen Pharma Corp. has recorded 27 reports. Market capitalisation: €379.7m. The latest transaction was filed on 9 September 2026 (50 - Grant of options). Among the most active insiders: Ruffolo, John. The full history is openly available.
27
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
16 shares@ CA$2.07620.2% of flowCommon SharesTSXSEDI:4725857
Canonical exit: 25 Aug 2026 (T+90)
25 of 27 declarations
About NervGen Pharma Corp.
NervGen Pharma Corp. is a biopharmaceutical company focused on developing treatments for neurological diseases. It is listed on the Toronto Stock Exchange under the symbol XTSE.